Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies.

Abstract excerpt

Highly effective modulator therapies dramatically improve the prognosis for those with cystic fibrosis (CF). The triple combination of elexacaftor, tezacaftor, and ivacaftor (ETI) benefits many, but not all, of those with the most common F508del mutation in the CF transmembrane conductance regulator (CFTR). Here, we showed that poor sweat chloride concentration responses and lung function improvements upon...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzodioxoles
• Share to Cyclooxygenase 2
• Share to Cystic Fibrosis
• Share to Cystic Fibrosis Transmembrane Conductance Regulator